louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05228873: Comparison of Quality of Life After Discharge of the Mild and Moderate COVID-19 Patients With or Without Herbal Medicine
Official title: Comparison of Quality of Life 3 Months After Discharge of the Mild and Moderate COVID-19 Patients With or Without Herbal Medicine (Shen Cao Gan Jiang Tang) in the Acute Stage
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19 Pandemic
Quality of Life
Lead sponsor: University of Medicine and Pharmacy at Ho Chi Minh City
Sponsor class: OTHER
First posted: 2022-02-08
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The mild and moderate COVID-19 patients who used the Shen Cao Gan Jiang Tang in the acute phase

Brief summary: The purpose of this study is to see how the acute stage COVID-19 treatments by use of herbal medicine (Shen Cao Gan Jiang Tang) affect quality of life and symptoms at 3 months after hospital discharge.

Detailed description: According to the theory of Traditional medicine, the patient will suffer damage to Qi and Fluid in the acute phase and lead to damaged Yin and Qi in the post COVID-19 period.

The Shen Cao Gan Jiang Tang has the effect of enhance the Protective Qi, generating Fluid, is applied to treat the mild and moderate COVID-19 in the acute phase in some hospitals in Ho Chi Minh City, Viet Nam. The hypothesis is that with the use of the Shen Cao Gan Jiang Tang, the Qi and Yin will reduce the damage, so that the patient has a better quality of life and fewer post COVID-19 symptoms compared with the standard of care group

Eligibility criteria: Inclusion Criteria:

* Patients able to understand and fill out a questionnaire
* From full 18 to 64 years old;
* Patients with the mild and moderate COVID-19 who used Shen Cao Gan Jiang Tang in the acute phase for intervention group.
* Participants enrolled in protocol NCT05055427.
* Voluntarily consented to participate in the study

Exclusion Criteria:

* Patient who are not able to complete 100% of the questionnaire Criteria for stopping the study
* The patient cannot be contacted after 04 calls, each call is at least 06 hours apart on the survey days.
* The patient does not want to continue participating in the study.

Primary outcomes:
measure: Quality of Life (QoL) questionnaire
timeFrame: 3 months
Secondary outcomes:
measure: Post COVID-19 symptoms
timeFrame: 3 months
Other outcomes:
Locations:
city: Ho Chi Minh
country: Vietnam
facility: University of Medicine and Pharmacy at Ho Chi Minh City
Study officials:
affiliation: University of Medicine and Pharmacy at Ho Chi Minh City
name: Nguyen Van Dan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04400773: Upper Body Plyometrics in Junior Male Cricket Fast Bowlers
Official title: The Impact of Upper Body Plyometrics on Junior Male Cricket Fast Bowlers' Delivery Speed in Guyana
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sport Performance
Lead sponsor: The University of The West Indies
Sponsor class: OTHER
First posted: 2020-05-26
Enrollment: 30
Sex: MALE
Minimum age (years): 15
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two group pre-test post-test.
Primary purpose: OTHER

Brief summary: A six-week upper body plyometric training program will be used to investigate its impact on fast bowling speed in junior male cricket players in Guyana, using a Stalker Sport 2 radar gun.

Detailed description: This randomized pilot study will compare the effects of a six-week Upper Body Plyometric program with Upper Body Strength Training. After gaining ethical approval and baseline bowling speeds recorded, thirty under 19 club level fast bowlers will be assigned to two groups to complete either an upper-body plyometric or strength training program. Each group will participate in three (3) supervised exercise intervention sessions per week. Each 65-minute session will consist of a warm-up and cool-down program in addition to specific and routinely progressed upper body exercises as per each group's protocol. At the end of the intervention period, their bowling speeds will again be measured using a Stalker Sport 2 radar gun.

Eligibility criteria: Inclusion Criteria:• Only male athletes were admitted to the study.

* Athletes must have been practicing the art of fast bowling for at least one year at the club level.
* Athletes must have been between the ages of 15-19.
* Athletes must have been uninjured at the time of commencement of the study.

Exclusion Criteria:

* • Were outside of the age group being surveyed at the time of the study,

  * Had been practicing fast bowling at the club level for less than one (1) year,
  * Was injured at the time of commencement or within one year of the study.
  * Could not commit to full participation in the study's training regimes.
  * Received surgery in the three years prior to the study or had undergone rehabilitation within the past year.
  * Were currently engaged in plyometric training as this may confound the study.

Primary outcomes:
measure: Bowling speed
timeFrame: After 6 weeks of exercise training
Secondary outcomes:
Other outcomes:
Locations:
city: Georgetown
country: Guyana
facility: Cricket Association-Clubs
city: Georgetown
country: Guyana
facility: Cricket Association-Clubs
Study officials:
References:
Clinical trial NCT00338273: A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Bipolar Disorder
Keywords: Bipolar I disorder with major depressive episode
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Otsuka America Pharmaceutical
First posted: 2006-06-20
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.


Eligibility criteria: Inclusion Criteria:

* Outpatients
* Must sign informed consent prior to protocol-related procedures

Exclusion Criteria:

* Women who are pregnant, trying to become pregnant, or nursing
* Significant risk of committing suicide
* Any serious unstable medical conditions

Primary outcomes:
measure: Mean change from baseline to endpoint (Week 8 last observation carried forward = LOCF) on the Montgomery-Asberg Depression Rating Scale (MADRS) total score
Secondary outcomes:
measure: Mean change from baseline to endpoint on the Clinical Global Impression-Bipolar Version, severity of illness score (depression)
Other outcomes:
Locations:
city: Durham
country: United States
facility: Local Institution
state: North Carolina
city: Ahmedabad
country: India
facility: Local Institution
state: Gujarat
city: Chennai
country: India
facility: Local Institution
city: Delhi
country: India
facility: Local Institution
city: Hyderabad
country: India
facility: Local Institution
city: Lucknow
country: India
facility: Local Institution
city: Mumbai
country: India
facility: Local Institution
city: Vishakhapatnam
country: India
facility: Local Institution
Study officials:
References:
Clinical trial NCT01666873: Correlation Between Alignment of Lower Limb and Clinical Outcome After Total Knee Prosthesis.
Official title: Correlation Between Alignment of Lower Limb and Clinical Outcome After Total Knee Prosthesis.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoarthritis of the Knee Joint
Keywords: osteoarthritis
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2012-08-16
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People who have osteoarthritis of the knee joint and receive a total knee prosthesis.

Brief summary: Evaluation of the clinical results after total knee prosthesis, and correlation with the alignment of the lower limb.

Radiological measurements by means of 3D technology will be performed. The clinical result will be stipulated by means of standardized questionnaires (KOOS, KSS and Oxford knee score-questionnaire).


Eligibility criteria: Inclusion Criteria:

* Patient with osteoarthritis of the knee joint, without severe bone deformation

Exclusion Criteria:

* none

Primary outcomes:
measure: Clinical results after total knee prosthesis with standardized questionnaires after 6 months
timeFrame: 6 months after total knee prosthesis
measure: Clinical results after total knee prosthesis with standardized questionnaires after 12 months.
timeFrame: 12 months after total knee prosthesis
measure: Clinical results after total knee prosthesis with standardized questionnaires after 24 months.
timeFrame: 24 months after total knee prosthesis
Secondary outcomes:
measure: Alignment of lower limb, slope of lateral and medial tibial plateau, femoral slope.
timeFrame: 6 months after total knee prosthesis
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: Ghent University Hospital
Study officials:
affiliation: University Hospital, Ghent
name: Jan Victor, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00999973: Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia
Official title: Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Myopia
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2009-10-22
Sex: ALL
Minimum age (years): 19
Maximum age (years): 60
Standard ages: ADULT

Brief summary: In this study 126 eyes in 63 patients with moderate bilateral myopia and astigmatism between -3 and -5 (SE difference between two eyes should not be more than 0.75 and the residual corneal thickness\>350 μ ) were entered in the study. One eye went randomly under PRK with mitomycin C 0.02% in 15 min and then the other eye went under the operation without MMC. UCVA,BCVA, refractory error after the operation and the number of endothelial cells before and after the surgery would be compared in 6 months.


Eligibility criteria: Inclusion Criteria:

* 19 \< age \< 60
* Refractory error stabled for at least one year
* No corneal pathology
* -3 \< bilateral myopia and astigmatism \< -5 with no difference more than 0.75 between 2 eyes

Exclusion criteria:

* Keratoconus
* Ectatic corneal disease
* Glaucoma
* Corneal dystrophy
* Lens changes affecting the visual acuity
* Anterior or posterior uveitis
* Corneal scar

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Ophthalmic Research Center
Study officials:
References:
Clinical trial NCT06805773: Evaluating the Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic
Official title: Evaluating the Use of Educational Videos in a Medical Oncology Sarcoma Clinic to Improve Patient Knowledge and Satisfaction.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Sarcoma
Keywords: Education
Sarcoma
Lead sponsor: Mount Sinai Hospital, Canada
Sponsor class: OTHER
First posted: 2025-02-03
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study aims to evaluate how sarcoma-specific educational videos improve patients' knowledge of their disease and treatment options before their first clinic appointment.

Participants will watch four educational videos before their first appointment with a medical oncologist. Participants will be asked to complete surveys to assess their understanding of sarcoma and its treatment options before and after their first medical oncology clinic appointment.


Eligibility criteria: Inclusion Criteria:

1. Signed written and voluntary informed consent.
2. Have histologically documented advanced metastatic sarcoma, or is a caregiver of a patient with histologically documented advanced metastatic sarcoma.
3. Age ≥ 18 years.
4. Have not received any previous systemic treatment for sarcoma, or is a caregiver of a sarcoma patient who has not received any previous systemic treatment for sarcoma.
5. Willing/able to complete questionnaires.
6. Able to read and write in English.

Exclusion Criteria:

1. Inability to provide informed consent.
2. Previously seen by a medical oncologist for their sarcoma.

Primary outcomes:
measure: Assess differences in patients' and caregivers' knowledge and perceptions of sarcoma and its treatment before and after educational intervention
timeFrame: up to 2 weeks (date when given appointment and date of first appointment)
Secondary outcomes:
measure: Assess understandability and actionability of sarcoma educational videos.
timeFrame: up to 2 weeks (date when given appointment and date of first appointment)
measure: Assess understandability and actionability of sarcoma educational videos.
timeFrame: up to 2 weeks (date when given appointment and date of first appointment)
measure: Assess patient's and caregivers' satisfaction with the educational videos
timeFrame: up to 2 weeks (date when given appointment and date of first appointment)
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Mount Sinai Hospital
state: Ontario
Study officials:
References:
Clinical trial NCT06977373: The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer
Official title: The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Colorectal Cancer
Lead sponsor: Yunnan Cancer Hospital
Sponsor class: OTHER
First posted: 2025-05-18
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Spectral CT was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.


Eligibility criteria: Inclusion Criteria:

1. Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
2. Age \> 18 years.
3. Patients suspected of having colorectal cancer.
4. Patients who have signed the informed consent form.

Exclusion Criteria:

1. Severe cardiac, pulmonary, or renal insufficiency.
2. Allergy to iodine-based contrast agents.
3. Inability to cooperate with the CT examination.
4. Poor image quality of the Quark Spectral CT scan.
5. Women who are pregnant or breastfeeding.

Primary outcomes:
measure: Pathological TNM staging
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Kunming
country: China
facility: Yunnan Cancer Hospital
state: City
Study officials:
affiliation: Ethics Committee of Yunnan Provincial Cancer Hospital
name: Lianhua Ye
role: STUDY_DIRECTOR
References:
Clinical trial NCT05648773: COVID-19 Booster Incentives
Official title: COVID-19 Booster Incentives in a County-Run Health System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Booster Message
Booster Message + Financial Incentive
Lead sponsor: University of Southern California
Sponsor class: OTHER
Collaborators: name: J-PAL North America
First posted: 2022-12-13
Enrollment: 57893
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this work is to understand whether small financial incentives and messaging can increase the take-up of COVID-19 boosters among patients empaneled at a county public health system. The motivation for this work is the relatively low take-up of COVID-19 boosters. In California, where our experiment is based, only 59% of the population has been boosted, with only 13% receiving the recommended bivalent booster (State of California, 2022).


Eligibility criteria: Inclusion Criteria:

1. Age: 18 and above
2. At least one COVID-19 vaccination (primary series or monovalent booster) but no vaccination dose within the past 2-months.
3. Active phone number or email

Exclusion Criteria:

1. Opt-out of health system messaging

Primary outcomes:
measure: Vaccine booster
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Martinez
country: United States
facility: Contra Costa Health Plan
state: California
Study officials:
References:
Clinical trial NCT00396773: Neonatal Brain Waves After Electrocoagulation
Official title: Neonatal Brain Waves After Electrocoagulation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Epilepsy
Keywords: electrocoagulation,pregnancy,brian waves
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2006-11-07
Enrollment: 60
Sex: ALL
Minimum age (years): 1
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: Electrocoagulation effect of neonatal brain waves after cesarean section

Detailed description: Electrocoagulation is used for bleeding control on usual basis in cesarean sections and other surgical procedures .

We are planning to test the effect of electrocoagulation unipolar on neonatal brain waves compared with neonates that were exposed to bipolar electrocoagulation .Bipolar electrocoagulation should have les of an effect because of it coagulates in a close ,closed electrical cycle .

Eligibility criteria: Inclusion Criteria:

* term normal newborn after normal pregnancy after elective cesarean section

Exclusion Criteria:

* any fetal or neonatal disease or condition that may affect brain waves

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Contact Arik Tzukert,DMD
Study officials:
affiliation: Hadassah University Medical Organization
name: David Mankuta
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rosen I. The physiological basis for continuous electroencephalogram monitoring in the neonate. Clin Perinatol. 2006 Sep;33(3):593-611, v. doi: 10.1016/j.clp.2006.06.013.
Clinical trial NCT00905073: Low Dose Cyclosporin and Methotrexate Therapy in Diabetes
Official title: Low Dose Cyclosporin and Methotrexate Therapy in New Onset Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 1 Diabetes Mellitus
Keywords: type 1 diabetes mellitus
cyclosporin
methotrexate
renal function
Lead sponsor: Georgetown University
Sponsor class: OTHER
First posted: 2009-05-20
Enrollment: 8
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether treatment with low dose cyclosporin and methotrexate can inhibit the development of new onset diabetes mellitus

Detailed description: Objective: Although high doses of cyclosporin (cyclo) inhibits the development of type 1 diabetes mellitus, its usefulness is limited by its toxicity. Since methotrexate (mtx) and cyclo synergistically inhibit other disease processes, we hypothesized that low dose cyclo and mtx therapy could safely induce remission.

Research Design and Methods: In an open pilot study, insulin dose and glycemic control will be compared in children with new onset Type 1 diabetes administered cyclo at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day and mtx 5 mg/kg/day for one year with control children. After 6 weeks, doses were adjusted to maintain blood cyclo levels to 100-200 ng/ml.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Type1 diabetes mellitus and be obtaining insulin therapy for less than 4 weeks

Exclusion Criteria:

* Ketoacidosis
* Body weight over 110% of ideal weight
* Condition where immunosuppression is contraindicated
* Abnormal liver or renal function tests

Primary outcomes:
measure: insulin dose
timeFrame: one year
Secondary outcomes:
measure: renal function
timeFrame: one year
Other outcomes:
Locations:
city: Washington DC
country: United States
facility: Georgetown University
state: District of Columbia
Study officials:
affiliation: Georgetown University
name: Douglas Sobel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01625273: Supplementation of Infant Formula With Synbiotics
Official title: Supplementation of Infant Formula With the Synbiotics (Lactobacillus Paracasei Ssp. Paracasei Strain F19 and Fructo- and Galactooligosaccharides).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infant Formula
Keywords: F19
Lactobacillus paracasei paracasei
Lead sponsor: Arla Foods
Sponsor class: INDUSTRY
First posted: 2012-06-21
Enrollment: 182
Sex: ALL
Minimum age (years): 1
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The primary hypothesis is that Lactobacillus paracasei ssp. paracasei strain F19 in an infant formula containing FOS/GOS is safe and tolerable for use in infants from 0 to 6 months.


Eligibility criteria: Inclusion Criteria:

* healthy infants of mothers who voluntarily resigned completely from breastfeeding
* infant age 28 days
* delivered between 38 and 42 weeks of gestation
* vaginal delivery
* birth weight \> 2700 g and \< 4200 g
* parent or the subject's legal representative has to speak and understand Polish

Exclusion Criteria:

* fully or partially breastfed infants
* malformations, handicaps or congenital diseases that could affect normal growth
* treatment with antibiotics
* fed infant formula with pre- and/or probiotics

Primary outcomes:
measure: Growth (body weight, length, head circumference)
timeFrame: From 28 days to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Samodzielny Publiczny Dziecięcy Szpital Kliniczny
Study officials:
affiliation: Samodzielny Publiczny Dziecięcy Szpital, Warsaw
name: Hania Szajewska, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Samodzielny Publiczny Dziecięcy Szpital Kliniczny, Warsaw
name: Jacek Witwicki, MD
role: PRINCIPAL_INVESTIGATOR
References: